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sIntroduction
In many industries, entrepreneurs are asked to un-dergo a process called “frugal innovation.” This pro-cess supports advances in technology that drive
own spending and improve results or leave them static.
ikewise, in the healthcare system, there is a shift occur-
ing calling for a reduction in spending. Key to this shift
ill be implementation of innovative devices brought
orward by entrepreneurs. Although technologymay add
o costs in the near-term, most of the empirical analysis
hows that the aggregate benefıts vastly outweigh expen-
itures. However, several regulatory and perceptual chal-
enges exist that entrepreneurs will have to overcome.
Background
Innovations inmedical technology are cited frequently as
one of the drivers of increased healthcare costs. But less
empirical attention is paid to the short- and long-term
economic benefıts of these innovations. Analyses are of-
ten biased in the direction of accentuating the costs be-
cause they are realized immediately with the outlays
showing up on current budgets.1 But the benefıts of a new
invention can accrue over many years.
The benefıts of medical technology can be diffıcult to
measure in economic terms, such as increases in life span
or reductions in morbidity from a disease. Accordingly,
technology can also turn procedures that were previously
diffıcult to perform or had to be undertaken in high-cost
settings into less-invasive, less-risky, and less-costly en-
deavors. Innovation has been a transformative force in
enabling improvements in health. From 1980 to 2000,
new diagnostic and treatment paradigms helped drive a
4% increase in life expectancy in the U.S., a 16% decrease
in annual mortality rates, and a 25% decline in disability
rates for the elderly.2
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CC BY-Still, many attribute a large share of the age-adjusted
growth in per-capita medical spending in recent decades
to innovation: the cost of new devices and the procedures
they enable. However, the real question is whether the
benefıts of innovation are increasing faster or slower than
the costs.3 The clearest way to solve long-term fıscal chal-
lenges with public health programs such asMedicare and
Medicaid is to improve healthcare productivity to achieve
more medical benefıt for each dollar spent on healthcare
programs. Consequently, continued advances in medical
technology are going to be an important part of this
improved productivity.
The role of entrepreneurs, healthcare technology inno-
vations, and their perceived costs of implementation have
been contested recently.On the one hand, some research-
ers argue that innovations in technology (coupled with
weak cost-containment strategies) generally increase
healthcare costs in the U.S. because they are adopted
more readily because of the payment system in place and
a lack of regulatory constraints. Others disagree, citing
the diffıculty for entrepreneurs to make headway with
their inventions because powerful institutions (regula-
tors, medical specialists, insurance companies, and hos-
pitals) fıght against simpler, cheaper alternatives that
threaten their livelihoods. Instead, these researchers be-
lieve the healthcare industry needs to open its doors to
market forces and embrace disruptive technologies and
business models that, in the short term, may threaten the
status quo but in the long termwill improve the quality of
health care.
Exemplifying a common argument, Bodenheimer4 ar-
ues that, by comparisonwith other countries, greater avail-
bility of new technologies in the U.S. is associated with
reater per-capita use andhigher spending.He submits that
ew technologies diffuse faster in the U.S. because of easier
cceptance by the medical profession largely because of the
enerous fee-for-service payment system (which does not
xist in other countries) and the lack of regulatory con-
traints. Consequently, this situation makes new technolo-
iesprone toover- (unnecessary)use,which, therefore, con-
ributes to greater costs. Associated costs can be contained if
ome limits areplacedondiffusionof the technology, partic-
larly through HMOs and through the two mechanisms of
ier Inc. Am J Prev Med 2013;44(1S1):S43–S47 S43
NC-ND license.
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S44 Gottlieb and Makower / Am J Prev Med 2013;44(1S1):S43–S47Medicare expenditure caps and global budgets (in which
expenditures for services are predetermined, and the costs
for those services may not exceed the budgeted amount).
In a counter-argument, Christensen and colleagues5
discuss how the process of innovation (disruption) works:
It starts with an innovation sneaking in unnoticed while
dominant players in the market, intent on improving
their products or services beyond most consumers’
needs, are not paying attention. In time, the innovations
improve to the point where they meet the needs of the
majority of users and become adopted.
This natural process of disruption will enable building
a new healthcare system characterized by lower costs,
higher quality, and greater convenience. The most-
powerful disruptions across industries have enabled
larger populations of less-skilled people to do something
in a more-convenient, less-expensive setting. Examples
include the personal computer, the camera, the tele-
phone, and the photocopy machine. The same thing can
happen in the healthcare system: Less-expensive profes-
sionals in less-expensive settings can be enabled to do
progressively more–sophisticated things.
Both arguments have validity. However, further re-
search is needed to determine the long-term value of
healthcare innovations and barriers to their implementa-
tion. This analysis discusses each argument in depth.
Analysis
New devices make more medical problems accessible to
intervention, but there is also ample evidence that such
devices have lowered substantially the cost of resulting
procedures. Advances that enable procedures to be per-
formed through minimally invasive techniques such as
laparoscopy or arterial catheterization have turned exten-
sive surgeries into more-routine and less-costly endeav-
ors.6–8 Other devices have enabled procedures previously
erformed in hospitals to be moved into more-effıcient,
ess-expensive outpatient settings. In fact, inventions that
mprove productivity, forestall future morbidity, or im-
rove quality of life can provide substantial benefıts and
ltimately lead to future savings.
However, the potential benefıts posed by such devices
re being challenged by fıscal problems and the manage-
ent of Medicare and Medicaid. Notably, spending on
edical devices still represents a relatively small portion
f overall healthcare expenditures. A recent analysis by
he Boston Consulting Group shows that, since 1989,
ggregate spending on devices, as a percentage of total
ealthcare costs, has remained flat at about 5%. In 2009,
pending on medical devices totaled $147.0 billion or
.9% of total national health expenditures ($2.5 trillion).Moreover, government healthcare programs are said
to place a strong focus on the cost of new medical tech-
nologies and the contribution of these technologies to
overall healthcare spending. Part of the reason for this
focus is that actuaries often see a device for diagnosing
illness or enabling a surgery as not only requiring imme-
diate outlays but also triggering additional healthcare use
down the road. However, new technologies can extend
the scope of medicine to conditions once regarded as
beyond its boundaries.9 And the methods for scoring
he costs of a new medical technology do not currently
ake full measure of the dynamic effects of innovation
uch as the potential for greater productivity, improve-
ent in health, and the opportunity to forestall disease
hat might have otherwise required additional health-
are expenditures.
New technologies also confront the physician’s natural
esistance to change. Evenwhen the near-term cost-savings
re clear, there is sometimes substantial resistance to
dopting new technologies within specialty societies.
his is evident in cases where the technology may facili-
ate a change in the provider group offering the care,
eading to turf battles with respect to reimbursement.
ocieties or groups with more power can quash new
echnologies by creating fınancial disincentives to their
doption. Often these same professional societies also
xert substantial influence on policy. As a result, they can
mpede substantially value-based adoption of new
echnologies.
As a result of all these factors, public healthcare pro-
rams increasingly are reluctant to embrace new technol-
gies. Because policymakers are always searching for
hort-term savings, clamping down on the use of expen-
ive new medical devices is one immediate and obvious
nswer. But this response creates challenges for innova-
ors not only in getting reimbursement for their products
ut in getting funding for their development programs in
he fırst place.
Taken together, these factors could preclude further im-
rovements in healthcare productivity as a result of innova-
ion. Programs such as Medicare and Medicaid are deter-
ined to adopt policies that give them leverage over
eimbursement and coverage of new technologies. But they
eed to carefully evaluate the role that innovation plays in
owering healthcare costs by changing delivery models and
educing the short- and long-term burden of disease.
Measuring the Value of New Technology
Economists have tried to quantify the value of medical
innovation to society. A number of studies have exam-
ined the benefıts of technology on specifıc illnesses, such
www.ajpmonline.org
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Jas heart attacks and depression.10–12 Most of these stud-
ies have focused on new drugs.
One such analysis by David Cutler and colleagues
found that, from 1960 to 2000, average life expectancy
increased by 7 years. They attribute half of this gain to
improvements in health care. Comparing the value of a
year of life ($50,000–$200,000) to the study’s fınding that
each year of increased life expectancy costs about $19,900
in health spending (after adjusting for inflation), the au-
thors concluded that the increased spending, on average,
has been worth it.13
Fewer studies have looked specifıcally at the cost-savings
from medical devices. Although none of these studies is
dispositive, as a group, they generally show that medical
innovation has greatly increased value. New inventions fre-
quently yield direct costs in the short run. But, when judged
over the long run, they yield improvements in health whose
value is far greater than the increase in spending. Some
economists estimate that the value of the longer, better lives
that have resulted from translating new biomedical knowl-
edge into steps to prevent and slow diseases is worth many
trillions of dollars.14
There are some obvious examples of the ability of
technology to improve outcomes and lower costs. In the
1990s, improvement in the diagnosis and treatment of
coronary artery disease led to a dramatic reduction in
morbidity and mortality. Other factors, such as new
drugs and better rehabilitation, also played a substantial
role. But so did new devices that enabled more-accurate
diagnosis of heart disease (nuclear imaging); revascular-
ization of arteries (catheterization); and long-term man-
agement of damaged hearts (implantable defıbrillators).
In fact, as a result of these and similar advances, from
1980 to 2000, the overall mortality rate from myocardial
infarction fell by almost half, from 345.2 to 186.0 per
100,000 people.15 In a similar example, in the early 1980s,
relatively few seniors had cataracts removed because the
procedure often had complications, was diffıcult to per-
form, required hospital admission, and yielded imperfect
results. However, improvements in technology have en-
abled millions of seniors with more-modest visual im-
pairment to benefıt from less-invasive surgery.
Assessing the total value of these advances tends to be
imprecise. To estimate the population-wide benefıts of a
new technology, economists have applied several ap-
proaches.16 In one method, known as the residual ap-
proach, economists estimate the impact of technology on
healthcare spending by fırst estimating the impact of fac-
tors they can reasonably account for that drive increased
spending. These factorsmight include changes in income
or in the age of a population.17 The residual costs then are
attributed to changes in technology. Still, it should be d
anuary 2013noted that the factors included will largely drive the
fındings.
Harder to measure still are the aggregate benefıts of
individual technologies, largely because these benefıts
will be accrued by individual patients overmany years. As
a result, policymakers increasingly are willing to chal-
lenge coverage and pricing of new technologies. For ex-
ample, the Centers for Medicare & Medicaid Services
have expressed a desire to engage in reference pricing for
medical devices by asserting “Least Costly Alternative
Authority.”18–20
Under this policy, Medicare deems differing ap-
proaches to a particular medical problem clinically inter-
changeable. This means that, if Medicare believes various
approaches yield similar outcomes, it only reimburses at
an amount equal to the least-costly approach. This puts
the onus on innovators to demonstrate to Medicare
(much as they are required to demonstrate to the FDA)
why their new products are suffıciently differentiated
from others and produce better outcomes to merit in-
creased reimbursement. This construct has the effect of
creating a second regulatory hurdle to the adoption of
new products.
Next Steps
Making the Economic Case
Recent developments are also changing the traditional
investment model for new medical technology. Increas-
ingly, to secure reimbursement, entrepreneurs are being
required to demonstrate that their inventions can lower
direct medical costs. This requirement, in turn, has be-
come an increasingly common criterion by which in-
vestors judge—and invest in development of—tech-
nologies. Before development is funded, entrepreneurs
must demonstrate how their devices will show a “value
proposition.”
One prominent article, written by David Cassak in the
publication In Vivo,21 framed the issue in the following
anner: “Payors, providers, physicians, and perhaps
ven patients are now willing to discount the absolute
alue of innovative technology advances and accept a
ompromise—equal clinical value in exchange for
reater systemwide cost-savings. And product compa-
ies will have to follow suit, much like healthcare services
ompanies have taken advantage of opportunities to re-
uce overall healthcare costs without reducing quality.
his phenomenon, in which new technology must focus
s much attention, if not more, on lowering costs as on
mproving outcomes, was referred to by Cassak as “neg-
tive innovation.”
This shift in attitude from the traditional model for
evelopment and commercialization ofmedical products
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outcomes is unique to medical devices. Stanford econo-
mist Victor Fuchs observes that most healthcare innova-
tions have historically focused largely or entirely on im-
proving outcomes. Very few focus on reducing direct
costs. Yet in other industries, in a process called “frugal
innovation,” it is common for advances in technology to
drive down spending, even as they improve results or
leave them static. Fuchs argues that we are going to see
more of an emphasis on technology that reduces costs,
with or without commensurate improvements in quality-
of-life or long-term outcomes.22
Cassak21 argues that the rationale underlying negative
innovation is not foreign to physicians and device com-
panies. He submits that one can point to technology
advances in many clinical areas such as the migration of
physicians from traditional surgeries to minimally inva-
sive procedures.While providing equal or improved out-
comes, these new technologies and approaches have re-
duced overall healthcare costs.
Of course, it is possible that these less-invasive ap-
proaches have increased use by making patients who
would have beenmedically excluded frommore-invasive
approaches now eligible. Specifıcally, these approaches
might have persuaded patients who previously opted to
forgo surgery, with its increased morbidity and longer
recovery time, to undergo the procedure. Therefore, the
proposition that less-cumbersome and less-risky proce-
dures will lower direct spending is hard to defend. In
many cases, the exact opposite is true.
These market developments create concerns for entre-
preneurs and their ability to develop technologies that
can satisfy these apparent demands. Part of the concern
relates to the regulatory process, which is ill equipped to
enable these opportunities. There is no regulatory scheme
that permits manufacturers to pursue new products
merely on the basis of the ability of a product to lower
healthcare delivery costs. Nor are there clear and effıcient
pathways to enable sponsors tomake economic claims. In
many respects, the regulatory process works at odds with
policy goals aimed to inspire notions of “value.”
The FDA was instructed, in the 1997 Food and Drug
Administration Modernization Act (FDAMA), to issue
guidance on how manufacturers should make economic
claims about their products. But the FDA still has not
delivered such guidance.23 The FDA also holds a conser-
vative view on comparative claims among products, gen-
erally requiring superiority studies. Although there are
arguments that the FDA should not use the cost-
effectiveness of treatments as a criterion in weighing
clearances and approvals, there should still be discussion
on fınding a way for sponsors to pursue those claims ontheir own. Such studies can play a valuable role toward
competition in the marketplace.
In recent years, the FDA, by increasing its regulatory
requirements, also has increased substantially the cost of
bringing new technologies to market.24,25 This aspect of
he process is born of internal issues relating to the agen-
y’s growing aversion to risk and challenges in managing
ts review processes. But it also reflects the pressure the
DA is under to impose new requirements on the review
nd approval of medical devices.
Some consumer advocates and politicians see regula-
ion as away to slow the introduction of new technologies
hat could lower healthcare costs. But exactly the opposite
s true. Increased regulation raises the cost of investment
nd development, which ultimately translates into higher
rices for the resulting technology. Regulatory barriers
lso reduce competition by limiting the number of new
roducts. On the other hand, when multiple forms of
ngioplasty catheters or implantable hips and knees were
ntroduced, they increased competition, forced new en-
rants to innovate, and lowered technology costs, making
rocedures more affordable and accessible.
All these developments are in conflict with the way
any technologies develop in the postmarket. Technol-
gy evolves through practical applications that allow
ractitioners to optimize its use. This is especially true
hen it comes to medical devices. Demands that new
evices demonstrate up-front savings could forestall the
ort of real-world deployment that eventually fınds the
ost-productive use for a new product.
Conclusion
Although technology may add to costs in the near term,
most of the empirical analysis shows that aggregate ben-
efıts vastly outweigh expenditures. Regulatory constructs
that determine coverage policies based on a static mea-
sure of a technology’s benefıts at the time of its introduc-
tion can underestimate dramatically the economic value
of the innovation. Such approaches can fail to capture
downstream development that takes place through the
practical application of a new tool in real-world medical
settings. Yet, new product developers increasingly are
being asked to make this case a priori, even though em-
pirical tools to demonstrate it are not available.
Of course, in an environment of tight budgets, asking a
payer to assume the burden of fınancing this practical,
postmarket development work—in the absence of proof
that the net benefıts will outweigh costs—is an increas-
ingly unlikely proposition. But public programs such as
Medicare are not ordinary payers. The decisions that
Medicare makes often set a ceiling on what will be reim-
bursed by private payers. The program’s outsized influ-
www.ajpmonline.org
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Jence on the marketplace makes it a key determinant of
what kinds of technologies will win adoption and, in-
creasingly and more importantly, which ventures get fı-
nanced in the fırst place.
As Medicare clamps down on its support for innova-
tion, these opportunities are being forgone. Data show
that even though overall healthcare expenditures over
recent years have increased, the percentage of costs at-
tributable to technology has remained flat. In view of
these fındings, innovation in technology offers perhaps
the best chance to tackle rising healthcare costs while
maintaining high-quality care.
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